Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Abstract In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor gr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stephen Johnston, Joyce O’Shaughnessy, Miguel Martin, Jens Huober, Masakazu Toi, Joohyuk Sohn, Valérie A. M. André, Holly R. Martin, Molly C. Hardebeck, Matthew P. Goetz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cf9cf9b9d25d4a93984071353e442e17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf9cf9b9d25d4a93984071353e442e17
record_format	dspace
spelling	oai:doaj.org-article:cf9cf9b9d25d4a93984071353e442e172021-12-02T17:44:59ZAbemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups10.1038/s41523-021-00289-72374-4677https://doaj.org/article/cf9cf9b9d25d4a93984071353e442e172021-06-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00289-7https://doaj.org/toc/2374-4677Abstract In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone-only disease, ECOG performance status, and treatment-free interval (TFI) from an additional 12-month follow-up (after final progression-free survival [PFS] readout). In the intent-to-treat population, after median follow-up of approximately 39 months, the updated PFS was 28.2 versus 14.8 months (hazard ratio [HR], 0.525; 95% confidence interval, 0.415–0.665) in abemaciclib versus placebo arms, respectively. Time to chemotherapy (HR, 0.513), time to second disease progression (HR, 0.637), and duration of response (HR, 0.466) were also statistically significantly prolonged with the addition of abemaciclib to AI. Treatment benefit was observed across all subgroups, as evidenced by objective response rate change from the addition of abemaciclib to AI, with the largest effects observed in patients with liver metastases, progesterone receptor-negative tumors, high-grade tumors, or TFI < 36 months. Extended follow-up in the MONARCH 3 trial further confirmed that the addition of abemaciclib to AI conferred significant treatment benefit to all subgroups, including those with poorer prognosis.Stephen JohnstonJoyce O’ShaughnessyMiguel MartinJens HuoberMasakazu ToiJoohyuk SohnValérie A. M. AndréHolly R. MartinMolly C. HardebeckMatthew P. GoetzNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Stephen Johnston Joyce O’Shaughnessy Miguel Martin Jens Huober Masakazu Toi Joohyuk Sohn Valérie A. M. André Holly R. Martin Molly C. Hardebeck Matthew P. Goetz Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
description	Abstract In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone-only disease, ECOG performance status, and treatment-free interval (TFI) from an additional 12-month follow-up (after final progression-free survival [PFS] readout). In the intent-to-treat population, after median follow-up of approximately 39 months, the updated PFS was 28.2 versus 14.8 months (hazard ratio [HR], 0.525; 95% confidence interval, 0.415–0.665) in abemaciclib versus placebo arms, respectively. Time to chemotherapy (HR, 0.513), time to second disease progression (HR, 0.637), and duration of response (HR, 0.466) were also statistically significantly prolonged with the addition of abemaciclib to AI. Treatment benefit was observed across all subgroups, as evidenced by objective response rate change from the addition of abemaciclib to AI, with the largest effects observed in patients with liver metastases, progesterone receptor-negative tumors, high-grade tumors, or TFI < 36 months. Extended follow-up in the MONARCH 3 trial further confirmed that the addition of abemaciclib to AI conferred significant treatment benefit to all subgroups, including those with poorer prognosis.
format	article
author	Stephen Johnston Joyce O’Shaughnessy Miguel Martin Jens Huober Masakazu Toi Joohyuk Sohn Valérie A. M. André Holly R. Martin Molly C. Hardebeck Matthew P. Goetz
author_facet	Stephen Johnston Joyce O’Shaughnessy Miguel Martin Jens Huober Masakazu Toi Joohyuk Sohn Valérie A. M. André Holly R. Martin Molly C. Hardebeck Matthew P. Goetz
author_sort	Stephen Johnston
title	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
title_short	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
title_full	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
title_fullStr	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
title_full_unstemmed	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
title_sort	abemaciclib as initial therapy for advanced breast cancer: monarch 3 updated results in prognostic subgroups
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cf9cf9b9d25d4a93984071353e442e17
work_keys_str_mv	AT stephenjohnston abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT joyceoshaughnessy abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT miguelmartin abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT jenshuober abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT masakazutoi abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT joohyuksohn abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT valerieamandre abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT hollyrmartin abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT mollychardebeck abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups AT matthewpgoetz abemaciclibasinitialtherapyforadvancedbreastcancermonarch3updatedresultsinprognosticsubgroups
_version_	1718379614573690880

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Ejemplares similares